semaglutide immunoassay fda cleared test detection immunoassay LupinInNews: Lupin announced that it has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Applications for Liraglutide Injection Single-Patient-Use semaglutide immunoassay fda cleared test

At JosephCareRX, our weight specialists are dedicated to providing our patients with the latest and most effective treatment options for managing type 2 diabetes and supporting healthy weight loss

Dementia symptoms may improve with treatment

What our clients say Discover inspirational transformation stories from real Agile Telehealth members

Guaranteed analysis: This is where you'll find the percentages of the most important nutrients in the food: protein, fat, fiber, and moisture

Roche to present new data advancing its obesity portfolio at the American Diabetes Associations 2026 Scientific Sessions 2026-06-01 Late-breaking Phase II data highlight enicepatides (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity Late-breaking data from the Phase II ZUPREME-1 trial showcase petrelintides efficacy, safety, and compelling tolerability profile, which has the potential to redefine the weight management experience for people living with overweight or obesity A Phase II multi-arm trial evaluating enicepatide and petrelintide fixed-dose combinations will be initiated towards mid-2026 to develop a differentiated treatment option Basel, 1 June 2026 - Roche (SIX: RO, ROP